REFERENCES

• TamaiI.TsujiA.Transporter mediated permeation of drugs across the blood brain barrier.J Pharrn Sci.20008913711388
   PubMed Web of Science ®Google Scholar
• Kullak UblickGA.FischT.OswaldM.et al.Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain.FEBS Lett.19984241731769539145
   PubMed Web of Science ®Google Scholar
• KusuharaH.SugiyamaY.Efflux transport systems for drugs at the blood brain barrier and blood-cerebrospinal fluid barrier (Part 1).Drug Discov Today.2001615015611165188
   PubMed Web of Science ®Google Scholar
• KusuharaH.SugiyamaY.KusuharaH.SugiyamaY.Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2).Drug Discov Today.2001620621211173268
   PubMed Web of Science ®Google Scholar
• VerganiP.BassoC.MenseM.NairnAC.GadsbyDC.Control of the CFTR channel's gates.Biochem Soc Trans.200533(Pt 5)1003100716246032
   PubMed Web of Science ®Google Scholar
• HergetM.TampeR.Intracellular peptide transporters in human - com partmentalization of the “peptidome.”Pfluge's Arch.2006 5 18 [Epub ahead of print]
   Google Scholar
• Pauli MagnusC.LangT.MeierY.et al.Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy.Pharmacogenetics.2004149110215077010
   PubMedGoogle Scholar
• Fernandez-MarmiesseA.SalasA.VegaA.Fernandez-LorenzoJR.BarreiroJ.CarracedoA.Mutation spectra of ABCC8 gene in Spanish patients with hyperinsulinism of infancy (HI).Hum Mutat.20062721416429405
   PubMed Web of Science ®Google Scholar
• GueugnonF.VolodinaN.TaouilJE.et al.A novel cell model to study the function of the adrenoleukodystrophy-related protein.Biochem Biophys Res Commun.200634115015716412981
   PubMed Web of Science ®Google Scholar
• BekriS.KispalG.LangeH.et al.Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation.Blood.2000963256326411050011
   PubMed Web of Science ®Google Scholar
• StenirriS.BattistellaS.FermoI.et al.De novo deletion removes a conserved motif in the C-terminus of ABCA4 and results in cone-rod dystrophy.Clin Chem Lab Med.20064453353716681420
   PubMed Web of Science ®Google Scholar
• MichaelidesM.HardcastleAJ.HuntDM.MooreAT.Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis.Surv Ophthalmol.20065123252816644365
   PubMed Web of Science ®Google Scholar
• CirritoJR.DeaneR.FaganAM.et al.P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model.J Clin Invest.20051153285329016239972
   PubMed Web of Science ®Google Scholar
• StefkovaJ.PoledneR.HubacekJA.ATP-binding cassette (ABC) transporters in human metabolism and diseases.Physiol Res.20045323524315209530
   PubMed Web of Science ®Google Scholar
• RedzicZB.BiringerJ.BarnesK.et al.Polarized distribution of nucleoside transporters in rat brain endothelial and choroid plexus epithelial cells.J Neurochem.2005941420142616111480
   PubMed Web of Science ®Google Scholar
• SteuerH.JaworskiA.ElgerB.et al.Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier.Invest Ophthalmol Vis Sci.2005461047105315728564
   PubMed Web of Science ®Google Scholar
• HawkinsRA.PetersonDR.VinaJR.The complementary membranes forming the blood-brain barrier.IUBMB Life.20025410110712489636
   PubMed Web of Science ®Google Scholar
• GanongWF.Circumventricular organs: definition and role in the regulation of endocrine and autonomic function.Clin Exp Pharmacol Physiol.20002742242710831247
   PubMed Web of Science ®Google Scholar
• StrazielleN.KhuthST.Ghersi-EgeaJF.Detoxification systems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations.Adv Drug Deliv Rev.2004561717174015381331
   PubMed Web of Science ®Google Scholar
• EmerichDF.VasconcellosAV.ElliottRB.SkinnerSJ.BorlonganCV.The choroid plexus: function, pathology and therapeutic potential of its transplantation.Expert Opin Biol Ther.20044119120115268655
   PubMed Web of Science ®Google Scholar
• ltoK.SuzukiH.HorieT.SugiyamaY.Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport.Pharm Res.2005221559157716180115
   PubMed Web of Science ®Google Scholar
• Ghersi-EgeaJF.StrazielleN.Choroid plexus transporters for drugs and other xenobiotics.J Drug Target.20021035335712164384
   PubMed Web of Science ®Google Scholar
• HagenbuchB.GaoB.MeierPJ.Transport of xenobiotics across the bloodbrain barrier.News Physiol Sci.20021723123412433976
   PubMedGoogle Scholar
• LoscherW.PotschkaH.Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.Prog Neurobiol.200576227616011870
   PubMed Web of Science ®Google Scholar
• KerbR.Implications of genetic polymorphisms in drug transporters for pharmacotherapy.Cancer Lett.200623443316504381
   PubMed Web of Science ®Google Scholar
• TaylorEM.The impact of efflux transporters in the brain on the development of drugs for CNS disorders.Clin Pharmacokinet.200241819211888329
   PubMed Web of Science ®Google Scholar
• WacherVJ.WuCY.BenetLZ.Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.Mol Carcinog.1995131291347619215
   PubMed Web of Science ®Google Scholar
• KusuharaH.SugiyamaY.Active efflux across the blood-brain barrier: role of the solute carrier family.NeuroRx.20052738515717059
   PubMedGoogle Scholar
• OswaldC.HollandIB.SchmittL.The motor domains of ABC-transporters. What can structures tell us?Naunyn Schmiedebergs Arch Pharmacol.200637238539916541253
   PubMed Web of Science ®Google Scholar
• LeslieEM.DeeleyRG.ColeSP.Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.Toxicol Appl Pharmacol.200520421623715845415
   PubMed Web of Science ®Google Scholar
• eierI.JedlitschkyG.BuchholzU.ColeSP.DeeleyRG.KepplerD.The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates.J Biol Chem.199426927807278107961706
   PubMed Web of Science ®Google Scholar
• LeierI.JedlitschkyG.BuchholzU.et al.ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump.Biochem J.1996314(Pt 2)4334378670053
   PubMed Web of Science ®Google Scholar
• HoRH.KimRB.Transporters and drug therapy: implications for drug disposition and disease.Clin Pharmacol Ther.20057826027716153397
   PubMed Web of Science ®Google Scholar
• SoontommalaiA.VlamingML.FritschyJM.Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier.Neuroscience.200613815916916361063
   PubMed Web of Science ®Google Scholar
• CalatozzoloC.GelatiM.CiusaniE.et al.Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma.J Neurooncol.20057411312116193381
   PubMed Web of Science ®Google Scholar
• BrongerH.KonigJ.KopplowK.et al.ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier.Cancer Res.200565114191142816357150
   PubMed Web of Science ®Google Scholar
• KubotaH.IshiharaH.LangmannT.et al.Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis.Epilepsy Res.20066821322816361082
   PubMed Web of Science ®Google Scholar
• ToornvlietR.van BerckelBN.LuurtsemaG.et al.Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[C]verapamil and positron emission tomography.Clin Pharmacol Ther.20067954054816765142
   PubMed Web of Science ®Google Scholar
• SasongkoL.LinkJM.MuziM.et al.Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.Clin Pharmacol Ther.20057750351415961982
   PubMed Web of Science ®Google Scholar
• HagenbuchB.MeierPJ.Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties.Pflugers Arch.200444765366514579113
   PubMed Web of Science ®Google Scholar
• edigerMA.RomeroMF.PengJB.RolfsA.TakanagaH.BrufordEA.The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Introduction.Pflugers Arch.200444746546814624363
   PubMed Web of Science ®Google Scholar
• HagenbuchB.MeierPJ.The superfamily of organic anion transporting polypeptides.Biochim Biophys Acta.2003160911812507753
   PubMed Web of Science ®Google Scholar
• PizzagalliF.HagenbuchB.StiegerB.KlenkU.FolkersG.MeierPJ.Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.Mol Endocrinol.2002162283229612351693
   PubMed Web of Science ®Google Scholar
• GalicS.SchneiderHP.BroerA.DeitmerJW.BroerS.The loop between helix 4 and helix 5 in the monocarboxylate transporter MCT1 is important for substrate selection and protein stability.Biochem J.2003376(Pt 2)41342212946269
   PubMed Web of Science ®Google Scholar
• HalestrapAP.MeredithD.The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond.PflugersArch.2004447619628
   PubMed Web of Science ®Google Scholar
• EnersonBE.DrewesLR.Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery.J Pharm Sci.2003921531154412884241
   PubMed Web of Science ®Google Scholar
• BhattacharyaI.BojeKM.GHB (gamma-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier.J Pharmacol Exp Ther.2004311929815173314
   PubMed Web of Science ®Google Scholar
• BuschAE.KarbachU.MiskaD.et al.Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine.Mol Pharmacol.1998543423529687576
   PubMed Web of Science ®Google Scholar
• van MontfoortJE.MullerM.GroothuisGM.MeijerDK.KoepsellH.MeierPJ.Comparison of “type I” and “type II” organic cation transport by organic cation transporters and organic anion-transporting polypeptides.J Pharmacol Exp Ther.200129811011511408531
   PubMed Web of Science ®Google Scholar
• EvansWE.McLeodHL.Pharmacogenomics - drug disposition, drug targets, and side effects.N Engl J Med.200334853854912571262
   PubMed Web of Science ®Google Scholar
• ChooEF.KurnikD.MuszkatM.et al.Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier.J Pharmacol Exp Ther.20063171012101816537797
   PubMed Web of Science ®Google Scholar
• LeeW.GlaeserH.SmithLH.et al.Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.J Biol Chem.20052809610961715632119
   PubMed Web of Science ®Google Scholar
• O'KaneDJ.WeinshilboumRM.MoyerTP.Pharmacogenomics and reducing the frequency of adverse drug events.Pharmacogenomics.200341412517278
   PubMed Web of Science ®Google Scholar
• LinJH.YamazakiM.Clinical relevance of P-glycoprotein in drug therapy.Drug Metab Rev.20033541745414705869
   PubMed Web of Science ®Google Scholar
• LinJH.YamazakiM.Role of P-glycoprotein in pharmacokinetics: clinical implications.Clin Pharmacokinet.200342599812489979
   PubMed Web of Science ®Google Scholar
• SchinkelAH.SmitJJ.van TellingenO.et al.Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.Cell.1994774915027910522
   PubMed Web of Science ®Google Scholar
• SchwabM.EichelbaumM.FrommMF.Genetic polymorphisms of the human MDR1 drug transporter.Annu Rev Pharmacol Toxicol.20034328530712359865
   PubMed Web of Science ®Google Scholar
• BabaogluMO.BayarB.AynaciogluAS.et al.Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.Clin Pharmacol Ther.20057861962616338277
   PubMed Web of Science ®Google Scholar
• EichelbaumM.FrommMF.SchwabM.Clinical aspects of the MDR1 (ABCB1) gene polymorphism.Ther Drug Monit.20042618018515228162
   PubMed Web of Science ®Google Scholar
• SiddiquiA.KerbR.WealeME.et al.Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1 .N Engl J Med.20033481442144812686700
   PubMed Web of Science ®Google Scholar
• WeinshilboumR.Inheritance and drug response.N Engl J Med.200334852953712571261
   PubMed Web of Science ®Google Scholar
• CrivoriP.PoggesiI.Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs.Eur J Med Chem.2006 4 24 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• KonigJ.SeithelA.GradhandU.FrommMR.Pharmacogenomics of human OATP transporters.Naunyn Schmiedebergs Arch Pharmacol.200637243244316525793
   PubMed Web of Science ®Google Scholar
• HaasDW.SmeatonLM.ShaferRW.et al.Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an adult AIDS Clinical Trials Group Study.J infect Dis.20051921931194216267764
   PubMed Web of Science ®Google Scholar
• VerstuyftC.SchwabM.SchaeffelerE.et al.Digoxin pharmacokinetics and MDR1 genetic polymorphisms.Eur J Clin Pharmacol.20035880981212698307
   PubMed Web of Science ®Google Scholar
• RobertsRL.JoycePR.MulderRT.BeggEJ.KennedyMA.A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression.Pharmacogenomics J.2002219119612082591
   PubMedGoogle Scholar
• IllmerT.SchulerUS.ThiedeC.et al.MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.Cancer Res.2002624955496212208746
   PubMed Web of Science ®Google Scholar
• YamauchiA.leiriI.KataokaY.et al.Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene.Transplantation.20027457157212352921
   PubMed Web of Science ®Google Scholar
• SparreboomA.GelderblomH.MarshS.et al.Dif lomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.Clin Pharmacol Ther.200476384415229462
   PubMed Web of Science ®Google Scholar
• FujitaT.BrownC.CarlsonEJ.et al.Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1).Pharmacogenet Genomics.20051520120915864112
   PubMed Web of Science ®Google Scholar
• KerbR.BrinkmannU.ChatskaiaN.et al.Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences.Pharmacogenetics.20021259159512439218
   PubMedGoogle Scholar
• LeabmanMK.HuangCC.KawamotoM.et al.Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function.Pharmacogenetics .20021239540512142729
   PubMedGoogle Scholar
• DallasS.MillerDS.BendayanR.Multidrug resistance-associated proteins: expression and function in the central nervous system.Pharmacol Rev.20065814016116714484
   PubMed Web of Science ®Google Scholar
• ElferinkRO.GroenAK.Genetic defects in hepatobiliary transport.Biochim Biophys Acta.2002158612914511959455
   PubMed Web of Science ®Google Scholar
• MarzoliniC.TironaRG.KimRB.Pharmacogenomics of the OATP and OAT families.Pharmacogenomics.2004527328215102542
   PubMed Web of Science ®Google Scholar
• WakasugiH.YanoI.ItoT.et al.Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein.Clin Pharmacol Ther1998641231289695727
   PubMed Web of Science ®Google Scholar
• WeissJ.DormannSM.Martin-FacklamM.KerpenCJ.Ketabi-KiyanvashN.HaefeliWE.Inhibition of P-glycoprotein by newer antidepressants.J Pharmacol Exp Ther.200330519720412649369
   PubMed Web of Science ®Google Scholar
• Yasui-FurukoriN.KanekoS.Digitalis intoxication induced by paroxetine co-administration.Lancet.200636778816517279
   PubMed Web of Science ®Google Scholar
• BurnellJM.KirbyWM.Effectiveness of a new compound, benemid, in elevating serum penicillin concentrations.J Clin Invest.19513069770014850548
   PubMed Web of Science ®Google Scholar
• JariyawatS.SekineT.TakedaM.et al.The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.J Pharmacol Exp Ther.199929067267710411577
   PubMed Web of Science ®Google Scholar
• AyrtonA.MorganP.Role of transport proteins in drug absorption, distribution and excretion.Xenobiotica.20013146949711569523
   PubMed Web of Science ®Google Scholar
• ParkerRB.YatesCR.SobermanJE.LaizureSC.Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans.Pharmacotherapy.20032397998712921244
   PubMed Web of Science ®Google Scholar
• AszalosA.ThompsonK.YinJJ.RossDD.Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp).Anticancer Res.1999191053106410368654
   PubMed Web of Science ®Google Scholar
• BoydRA.SternRH.StewartBH.et al.Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.J Clin Pharmacol.200040919810631627
   PubMed Web of Science ®Google Scholar
• EnerothA.AstromE.HoogstraateJ.et al.Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction.Eur J Pharm Sci.20011220521411113639
   PubMed Web of Science ®Google Scholar
• FrohlichM.AlbermannN.SauerA.Walter-SackI.HaefeliWE.WeissJ.In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins.Biochem Pharmacol.2004682409241615548387
   PubMed Web of Science ®Google Scholar
• SadequeAJ.WandelC.HeH.ShahS.WoodAJ.Increased drug delivery to the brain by P-glycoprotein inhibition.Clin Pharmacol Ther.20006823123711014404
   PubMed Web of Science ®Google Scholar
• WangJS.DeVaneCL.GibsonBB.DonovanJL.MarkowitzJS.ZhuHJ.Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice.Psychopharmacology(Berl). 200618349049916283256
   PubMed Web of Science ®Google Scholar
• KeoghJP.KuntaJR.Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.Eur J Pharm Sci.20062754355416406207
   PubMed Web of Science ®Google Scholar
• KorenG.WoodlandC.ItoS.Toxic digoxin-drug interactions: the major role of renal P-glycoprotein.Vet Hum Toxicol.19984045469467211
   PubMedGoogle Scholar
• LeabmanMK.HuangCC.KawamotoM.et al.Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function.Pharmacogenetics.20021239540512142729
   PubMedGoogle Scholar
• DresserGK.SchwarzUl.WilkinsonGR.KimRB.Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.Clin Pharmacol Ther.200373415012545142
   PubMed Web of Science ®Google Scholar
• DresserGK.SpenceJD.BaileyDG.Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.Clin Pharmacokinet.200038415710668858
   PubMed Web of Science ®Google Scholar